All European Academies

Chinese Literature Giant Liu Zhenyun Comes to Nicosia Book Fest 2023, Sharing His Latest Translated Novels with Global Readers

Retrieved on: 
Tuesday, October 17, 2023
Language, Tofu, All European Academies, Open University of Cyprus, European University Cyprus, Tears, Country, Cook, Liu Zhenyun, European Academy of Sciences and Arts, Travel, University, Confucius, Donald Trump's Real Estate Tycoon, Collection, Strange bedfellows, Humour, Someone to Talk To, Dream, Philosophy, Literature, Laughter, Life, Confucius Institute, Ordre des Arts et des Lettres, Entertainment, Book

Sharing his thoughts on the book, he said, "This is a book that explores the links between a joke and a person.

Key Points: 
  • Sharing his thoughts on the book, he said, "This is a book that explores the links between a joke and a person.
  • "It is the most exciting edition of the Nicosia Book Fest I have attended.
  • He commended Liu Zhenyun's insightful and spellbound writing that resonates deeply with worldwide readers from all walks of life.
  • To date, Liu Zhenyun's books have sold over 15 million copies in China alone, with numerous adaptations gracing the silver screen.

Scientific Organizations Form International Group to Advance Ukrainian Science and Support Researchers; Breakthrough Prize Foundation Provides $3 Million

Retrieved on: 
Monday, October 24, 2022
Health policy, Royal Danish Academy of Sciences and Letters, Achievement, Polish Academy of Sciences, NAS, Mathematics, All European Academies, National Academy of Medicine, Organization, Research, German National Academy of Sciences Leopoldina, Technology, Student, Breakthrough Prize in Fundamental Physics, National Academy of Sciences of Ukraine, SEED, Australasian College of Physical Scientists and Engineers in Medicine, Letter, Royal Society, Physics, Federation, United Kingdom, Polish Academy of Arts and Sciences, Royal Danish Academy, Exile, Breakthrough Prize, National academy, Australian Academy of Science National Committees, French Academy of Sciences, National Academy of Engineering, Medical device, Pharmaceutical industry, Engineering, Science, Science

As the war in Ukraine continues, the global research community is increasingly concerned about immediate and lasting damage to the Ukrainian science enterprise and global research.

Key Points: 
  • As the war in Ukraine continues, the global research community is increasingly concerned about immediate and lasting damage to the Ukrainian science enterprise and global research.
  • "The world needs Ukrainian science, and Ukrainian science needs support," said Yuri Milner, founder of the Breakthrough Prize Foundation.
  • The Breakthrough Prize, renowned as the "Oscars of Science," recognizes the world's top scientists in the fields of life sciences, fundamental physics, and mathematics.
  • The Breakthrough Junior Challenge is an annual global video competition for students to inspire creative thinking about science.

Scientific Organizations Form International Group to Advance Ukrainian Science and Support Researchers; Breakthrough Prize Foundation Provides $3 Million

Retrieved on: 
Monday, October 24, 2022
Health policy, Royal Danish Academy of Sciences and Letters, Achievement, Polish Academy of Sciences, NAS, Mathematics, All European Academies, National Academy of Medicine, Organization, Research, German National Academy of Sciences Leopoldina, Technology, Student, Breakthrough Prize in Fundamental Physics, National Academy of Sciences of Ukraine, SEED, Australasian College of Physical Scientists and Engineers in Medicine, Letter, Royal Society, Physics, Federation, United Kingdom, Polish Academy of Arts and Sciences, Royal Danish Academy, Exile, Breakthrough Prize, National academy, Australian Academy of Science National Committees, French Academy of Sciences, National Academy of Engineering, Medical device, Pharmaceutical industry, Engineering, Science, Science

As the war in Ukraine continues, the global research community is increasingly concerned about immediate and lasting damage to the Ukrainian science enterprise and global research.

Key Points: 
  • As the war in Ukraine continues, the global research community is increasingly concerned about immediate and lasting damage to the Ukrainian science enterprise and global research.
  • "The world needs Ukrainian science, and Ukrainian science needs support," said Yuri Milner, founder of the Breakthrough Prize Foundation.
  • The Breakthrough Prize, renowned as the "Oscars of Science," recognizes the world's top scientists in the fields of life sciences, fundamental physics, and mathematics.
  • The Breakthrough Junior Challenge is an annual global video competition for students to inspire creative thinking about science.

New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Retrieved on: 
Friday, June 24, 2022
Health, Pharmaceutical, Loss of Sensation, Science, Patient, NMOSD, EC, Union, Aquaporin 4, B cell, All European Academies, Royal commission, European Academy of Neurology, Quality of life, Attack, NMO, CD19, Optic nerve, Astrocyte, Pain scale, Spinal cord, Woman, Autoimmunity, Safety, Risk, Instagram, Congress, Twitter, Forward-looking statement, LinkedIn, Experiment, Brain, Poster, Severe cognitive impairment, European Commission, Central nervous system, Neuromyelitis optica spectrum disorder, Autoantibody, Inflammation, Nasdaq, Cell, EMEA, Courage, Adult, Head, Paralysis, U.S. Securities and Exchange Commission, Spectrum disorder, EAN, Physician, Pharmaceutical industry, Medical device, Vaccine, Wood drying, EU, Facebook

These data are being presented during the 8th Congress of the European Academy of Neurology (EAN), June 25-28 in Vienna.

Key Points: 
  • These data are being presented during the 8th Congress of the European Academy of Neurology (EAN), June 25-28 in Vienna.
  • Fewer NMOSD-related hospitalisations were reported among those receiving UPLIZNA compared to those treated with placebo (mean, EU: 1.0 vs 2.0; non-EU: 1.0 vs 1.33).
  • NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes.
  • Baranello RJ, Avasarala, JR. Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances.

COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

Retrieved on: 
Thursday, February 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Private Securities Litigation Reform Act, Pain, Growth, Woman, Safety, Master of Science, NYSE, MS, RMS, All European Academies, Pregnancy, Glatiramer acetate, Neurology, Department, TEVA, Intention-to-treat analysis, Teva Pharmaceuticals, DOI, EAN, Research, Multiple sclerosis, Frequency, Teva, Failure, MD, TASE, Mother, Medication package insert, Incidence, Pregnancy rate, Chest pain, Patient, Review, Epidemiology, Doctor of Science, Travel, Flushing, BA, COVID-19, Department of Neurology, Xuanwu hospital, Itch, Rash, Investment, Annual report, Human, HIV disease progression rates, GA, Diagnosis, Compliance, MS1, Congress, COBRA, Swelling, Forward-looking statement, Medical device, Birth control, Pharmaceutical industry, EU, the COBRA Study, COPAXONE®, COPAXONE®, Teva, THE COBRA STUDY, COPAXONE®, COPAXONE®, TEVA

The COPAXONE label change provides breastfeeding patients with MS the choice to breastfeed while on MS treatment.

Key Points: 
  • The COPAXONE label change provides breastfeeding patients with MS the choice to breastfeed while on MS treatment.
  • Real-world safety of COPAXONE in Offspring of Breastfeeding and Treated Relapsing Multiple Sclerosis (RMS) patients (COBRA study) was retrospective data analysis using the national German Multiple Sclerosis and Pregnancy Registry.
  • COPAXONE (Glatiramer Acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
  • New Safety Data on treatment with COPAXONE (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis: COBRA study presented at the 7th Congress of the European Academy of Neurology (EAN).

DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

Retrieved on: 
Wednesday, October 20, 2021
Netherlands Cancer Institute, Biology, Dutch Cancer Society, MAP2K4, MAP, All European Academies, Colorectal cancer, Diagnosis, KRAS, Translational research, News, MEK, Valorisation, MKK4, DGAP, Cancer research, Research, Cancer Science, Liver regeneration, Quality of life, Justicia oncodes, Hepatocyte, Patient, Economy, Novo Holdings A/S, Cancer, Pharmaceutical industry, HepaRegeniX GmbH -, the Oncode Institute, Utrecht, HEPAREGENIX GMBH -, THE ONCODE INSTITUTE, UTRECHT

MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.

Key Points: 
  • MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
  • Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
  • About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
    The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.